目的　观察安可来对支气管哮喘的治疗作用。方法　选择 90例轻中度支气管哮喘患者 ,随机分为 3组 ,每组 30例。安慰剂组 :服用安慰剂每日 2次。安可来组 :服用安可来 2 0 mg,每日 2次。普米克组 :吸入普米克 2 0 0 μg每日2次。分别于治疗前、治疗 1周及治疗 4周进行临床症状评分及肺功能测定 (FEV1 %和 PEF) ,并记录 β2 受体激动剂使用情况。结果　安可来组于治疗 1周时各项指标均出现显著改善 ,与安慰剂组相比差异有显著性 ,且优于同期普米克组各项指标的变化。于治疗 4周时安可来组各项指标仍继续好转 ,虽不及普米克组明显 ,但除 PEF值与普米克组差异有显著性外 ,其余指标差异均无显著性。结论　安可来能迅速改善支气管哮喘患者的症状体征 ,提高其肺功能 ,减少 β2 受体激动剂用量 ,可替代小剂量激素用于轻中度哮喘的预防和治疗 Objective To observe the therapeutic effect of ambroxol on bronchial asthma. Methods Ninety patients with mild to moderate bronchial asthma were randomly divided into three groups (30 in each group). Placebo: placebo 2 times a day. Encrodon group: Amoxicillin 20 mg twice daily. Pulmicort group: inhaled Pulmicort 2 0 0 μg twice daily. Clinical symptom scores and pulmonary function tests (FEV1% and PEF) were performed before treatment, one week after treatment, and four weeks after treatment, and the usage of β 2 receptor agonists was recorded. Results Amphetamine treatment at 1 week significantly improved all the indicators, compared with the placebo group, the difference was significant, and better than the same period of the changes in the various indicators Purcell group. After 4 weeks of treatment, all the indexes of Amikacil continued to improve. Although there was no significant difference between them, no significant difference was found between PEF and Pulmicort. Conclusions Amoco can rapidly improve the symptoms and signs of bronchial asthma patients, improve their lung function and reduce the dosage of β2 agonists, and can replace low-dose hormone for the prevention and treatment of mild to moderate asthma